Business Context and Reporting Period
Company: Palatin Technologies, Inc. (PTN/PTNT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 2025
Business Overview: A biopharmaceutical company developing melanocortin receptor-based therapeutics. The Company sold worldwide rights to its commercial product, Vyleesi, to Cosette Pharmaceuticals in December 2023. Current focus is on obesity (bremelanotide + tirzepatide), dry eye disease (PL9643), and ulcerative colitis (PL8177).
Listing Status: Delisted from NYSE American on May 7, 2025, due to low stock price; now trades on OTC Pink Market under symbol "PTNT".
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $4,140,090 |
| Net Loss | $(4,811,420) | $(8,435,650) | $(15,077,551) | $(21,485,683) |
| Diluted EPS | $(0.18) | $(0.53) | $(0.68) | $(1.53) |
| Cash & Equivalents (End of Period) | $2,520,062 | $10,014,088 | $2,520,062 | $10,014,088 |
| Current Liabilities | $10,048,349 | $9,657,681 | $10,048,349 | $9,657,681 |
| Accumulated Deficit | $(456,844,101) | $(433,516,120) | $(456,844,101) | $(433,516,120) |
Liquidity: Cash burn for the nine months ended March 31, 2025, was approximately $17.2 million from operating activities. Management states cash is sufficient to fund operations into the second half of calendar year 2025.
Material Changes vs. Prior Period
- Revenue Elimination: Product revenue dropped to $0 for the nine months ended March 31, 2025, compared to $4.14 million in the prior year, following the sale of Vyleesi assets to Cosette.
- Expense Reduction: R&D expenses decreased to $12.9 million (9M 2025) from $17.7 million (9M 2024). SG&A expenses decreased to $5.2 million from $8.3 million, largely due to the elimination of Vyleesi selling costs.
- One-Time Gains: The Company recorded a $2.5 million gain on the sale of Vyleesi (settlement of purchase commitments) and a $416,000 gain on purchase commitments in the current period.
- Capital Structure: Significant equity dilution occurred via registered direct offerings and warrant exercises. Common shares outstanding increased from 17.9 million (June 2024) to 28.6 million (March 2025).
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for one year from the filing date due to recurring losses and negative cash flows. Additional financing is required.
- Clinical Pipeline Updates:
- Obesity: Topline results announced March 2025 showed co-administration of bremelanotide with tirzepatide demonstrated increased weight loss over tirzepatide alone.
- Ulcerative Colitis (PL8177): Topline results announced March 2025 showed one-third of patients achieved clinical remission vs. none in placebo.
- Dry Eye (PL9643): Completed Phase 3; positive Type C meeting with FDA concluded. Enrollment for next trial could commence H1 2025 depending on resources.
- Delisting Risk: Trading was suspended on NYSE American on May 7, 2025. The stock now trades on the OTC Pink Market. This may reduce liquidity and increase the cost of capital.
- Legal Proceedings: A breach of contract lawsuit was filed by H.C. Wainwright & Co. in February 2025 regarding an engagement agreement. The Company denies liability.
- Internal Controls: Disclosure controls and procedures were deemed not effective due to a material weakness in accounting for complex financial instruments.
Investor Verification Checklist
- Cash Runway: Verify if the $2.5 million cash balance is sufficient to fund the planned Phase 3 enrollment for PL9643 and continued development of PL8177 without immediate new financing.
- Financing Terms: Review the terms of the May 2025 public offering (Series F, G, H warrants) and the February 2025 registered direct offering to assess future dilution impact.
- Delisting Appeal: Monitor the status of the appeal against the NYSE American delisting determination.
- Contractual Obligations: Confirm the status of the $1.58 million accrued liability related to inventory purchase commitments for Vyleesi manufacturing.
- Legal Exposure: Track the progress of the Wainwright lawsuit and potential financial impact.